Suggestions
Yael Wexler-Cohen
Associate Director, Drug Product, Manufacturing Sciences & Technology
Yael Wexler-Cohen is the MSAT Director at bluebird bio.1 She is a leader driven by a proactive and creative mindset.1 Her LinkedIn profile highlights her proficiency in building and empowering teams, analyzing complex situations to create effective strategies, and possessing excellent communication skills across different levels of an organization.1
Wexler-Cohen's experience includes:
- Director at bluebird bio: Since December 2022, Yael leads the MSAT team, supporting the company's commercial programs, including plasmids, lentiviral vector, and DP manufacturing.1
- Associate Director at bluebird bio: From August 2021 to December 2022, she led the drug product group, supporting the manufacturing of autologous gene therapies at CMOs, playing a key role in pre-approval inspections and support for BLA responses.1
- Sr. Scientist at Amgen: From October 2018 to August 2021, Yael pioneered transformative optimization efforts for the technology transfer process of Amgen's large molecule clinical pipeline into the internal manufacturing site.1
- Scientist at Amgen: From October 2016 to September 2018, Yael led the drug product team for the ABP 938 program, a biosimilar to EYLEA® (aflibercept), where she built the development strategy, execution, and timelines, and collaborated with cross-functional leaders.1
- Scientist/Sr. Engineer at Amgen: From September 2013 to October 2016, Yael supported the successful commercialization efforts for Repatha® and Aimovig®, and was the process lead for Aimovig®, responsible for clinical manufacturing support.1
- Contract worker- Associate Scientist II at Amgen: From November 2012 to September 2013, Yael supported the successful commercialization efforts for Repatha® on accelerated timelines.1
Before her career in the biotechnology industry, Yael was a postdoctoral fellow at UCLA from July 2009 to November 2012, researching the fission mechanism of the hydrogenosome.1 She obtained her PhD in Biological Chemistry from the Weizmann Institute of Science (2002-2009), where she studied the HIV fusion mechanism.1 Prior to her scientific career, Yael was a professional ballet dancer with the Israeli Ballet dance company from 1989 to 2002.1